Designing polymer-peptide conjugates to target dipeptide repeat aggregates implicated in amyotrophic lateral
Vincent P Gray1, Zixian Cui1, Mackenzie Klepsig1
1Department of Chemical Engineering, University of Virginia, Charlottesville, Virginia 22903, USA. rl2qm@virginia.edu.
Journal of Materials Chemistry. B
|June 16, 2026
Summary
New polymer-peptide conjugates prevent the aggregation of toxic glycine-alanine (GA)n peptides, which are linked to amyotrophic lateral sclerosis (ALS). This discovery offers a promising new therapeutic strategy for ALS treatment.
Area of Science:
- Biochemistry
- Neuroscience
- Materials Science
Background:
- Toxic dipeptide repeats, such as glycine-alanine (GA)n, are implicated in amyotrophic lateral sclerosis (ALS) progression.
- ALS is a fatal neuromuscular disease with a critical need for novel therapeutic interventions.
Purpose of the Study:
- To develop and evaluate polymer-peptide conjugates as a potential therapeutic strategy for preventing or mitigating the effects of toxic peptide aggregation in ALS.
Main Methods:
- Co-incubation of polymer-peptide conjugates with glycine-alanine (GA)10 peptides.
- Optical density measurements to assess peptide aggregation.
- Transmission electron microscopy to visualize the effects of conjugates on peptide aggregation.
Main Results:
- Polymer-peptide conjugates effectively prevented the aggregation of (GA)10 when co-incubated.
- Conjugates also demonstrated the ability to disperse pre-aggregated (GA)10.
- These findings highlight the anti-aggregation properties of the developed conjugates.
Conclusions:
- Polymer-peptide conjugates show significant potential as a novel therapeutic approach for amyotrophic lateral sclerosis.
- This work contributes to the growing evidence supporting the use of polymer-peptide conjugates in therapeutic applications.
- Further research into these conjugates could lead to a new generation of ALS therapeutics.
